论文部分内容阅读
目的:观察疏肝健脾方药对非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)大鼠肝组织脂肪酸合成酶(fatty acid synthase,FAS)mRNA及蛋白表达的影响,探讨疏肝健脾方药抗大鼠NAFLD的作用机制。方法:雄性SD大鼠,分为正常组、模型组、健脾组、疏肝组、综合组。使用高脂肪乳剂灌胃造模,治疗组给予相应药物灌胃,8周后处死大鼠,检测血清转氨酶、血脂和肝脂水平;HE染色观察肝组织病理变化;RT-PCR和免疫组织化学方法检测肝组织FAS基因和蛋白的表达。结果:与模型组相比,各药物干预组大鼠血清AST、TC、TG含量和肝组织TC含量均显著下降(P<0.05,P<0.01),健脾组和疏肝组肝组织TG含量显著下降(P<0.05);光镜观察各药物均能改善大鼠肝细胞脂肪变性,以疏肝组更为显著;各用药组FAS mRNA表达水平和蛋白的表达均有下降(P<0.05),其中疏肝组表达的水平最低。结论:疏肝健脾方药能显著改善NAFLD大鼠脂质代谢紊乱,减轻肝损伤,具有良好的抗NAFLD的作用。其机制可能与下调FAS mRNA及蛋白表达有关。
Objective: To observe the effect of Shuganjianpi Decoction on the mRNA and protein expression of fatty acid synthase (FAS) in the liver of non-alcoholic fatty liver disease (NAFLD) in rats, Action mechanism of spleen recipe on rat NAFLD. Methods: Male SD rats were divided into normal group, model group, Jianpi group, Shugan group and comprehensive group. The rats in the treatment group were given gavage with the corresponding drugs, and the rats were sacrificed after 8 weeks. The levels of serum aminotransferases, lipids and hepatic lipids were measured. The pathological changes of the liver tissues were observed by HE staining. The expression of TNF-α was detected by RT-PCR and immunohistochemistry Liver tissue FAS gene and protein expression was detected. Results: Compared with the model group, the levels of AST, TC, TG and the contents of TC in liver tissue of rats in each intervention group were significantly decreased (P <0.05, P <0.01) (P <0.05). The results of light microscope showed that all the drugs could improve steatosis of hepatocytes in rats, which was more obvious in Shugan group. The expression of FAS mRNA and protein in each group were decreased (P <0.05) , Of which Shugan group the lowest level of expression. Conclusion: Shuganjianpi Recipe can significantly improve lipid metabolism disorders, reduce liver damage in NAFLD rats and has a good anti-NAFLD effect. The mechanism may be related to the down-regulation of FAS mRNA and protein expression.